InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (5 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
5
T+90 hit rate
50%
T+90 mean return
+3.8%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by McDonald Damien, Chief Executive Officer. Director active across 3 companies, notably Enovis CORP. Aggregated, 14 reports have been recorded. Breakdown: 0 buy · 5 sells. Total volume traded: €806k. Activity tracked since 5 May 2021. The latest transaction was filed on 12 May 2026 (Retenue fiscale). Regulator: SEC (Form 4). The full history is openly available.
Declarations14 total
12,634 shares@ US$25.990.020% mcap100.0% of flowCommon stock, par value $0.001SEC:0001193125-26-224739
12,634 shares@ US$25.990.020% mcap100.0% of flowCommon stock, par value $0.001SEC:0001193125-26-224739:0
96,296 shares0Common stock, par value $0.001SEC:0000950170-25-070898:0
2,220 shares@ US$42.5510.8% of flowOrdinary SharesSEC:0001639691-23-000041:0
3,213 shares0Ordinary SharesSEC:0001639691-23-000029:0
25,131 shares0Ordinary SharesSEC:0001639691-23-000019:0
2,220 shares@ US$54.5614.1% of flowOrdinary SharesSEC:0001639691-22-000120:0
2,784 shares@ US$81.500.0053% mcap33.8% of flowOrdinary SharesSEC:0001639691-22-000031:0
3,182 shares0Ordinary SharesSEC:0001639691-22-000027:0
5,167 shares0Ordinary SharesSEC:0001639691-22-000023:0
2,784 shares@ US$81.500.0052% mcap33.1% of flowOrdinary SharesSEC:0001639691-21-000118:0
2,784 shares@ US$81.500.0052% mcap100.0% of flowOrdinary SharesSEC:0001639691-21-000118
4,450 shares0Ordinary SharesSEC:0001639691-21-000051:0
4,450 sharesOrdinary SharesSEC:0001639691-21-000051
14 of 14 declarations
About McDonald Damien
Damien McDonald is the Chief Executive Officer of Enovis Corp and LivaNova PLC. He oversees the operations of these companies, which are leaders in health technology. McDonald is responsible for the overall strategy and innovation, aiming to improve patient outcomes and strengthen the company's market position.
